Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
about
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerRestoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and PreventionPrecision medicine in breast cancer: reality or utopia?Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Advancing Immunotherapy in Metastatic Breast Cancer.De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review.Single-cell heterogeneity in ductal carcinoma in situ of breast.Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.Immune Checkpoint Blockade for Breast Cancer.The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer.Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy.Immune characterization of breast cancer metastases: prognostic implications.Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.Is there a role for immunotherapy in HER2-positive breast cancer?Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this FieldMagnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer
P2860
Q26745446-E994E410-6C0E-4FBA-948D-ECCBE774C94DQ28067145-E64EA214-5708-42CC-8977-5A0ECB86A4B7Q33809114-24BC7575-28AC-4D82-9E19-9257108D503AQ37075648-F5404AAB-2EB8-4142-891A-98CBB47FB6FCQ37109643-0A941D8A-1A74-40B1-A32F-0396471852E4Q37160109-902C1B33-2A9A-482D-ABFF-2C34B5D7F1A5Q37536862-57EC94B6-418E-4B7F-A07A-4586E226CED5Q38373249-999333AE-BC7A-438A-9046-3EC61B186B88Q38387030-E8E71249-98C8-4FB0-93D2-8028BA876B53Q38648765-61ED86A3-5836-4617-8026-6D4E1F024215Q38661390-C4989C7C-D5E7-49A4-A407-27950C0B0949Q38734804-DBFBB51E-E70A-44FC-9CF1-5941CC1E4358Q38786102-12BABBB5-429D-4266-A20F-F3ECDDF9F473Q38823649-DC22F60A-9046-44B5-A95B-ED4811DCDB90Q39324161-5C56409B-FB69-49A4-947A-E6DE523C5AE2Q39421814-406AFA2F-7A41-4848-AA55-B99605E530DDQ39638185-92B191DD-9045-46E7-8AAE-0B805F935BE7Q40694392-7C9A2292-6D67-4022-8673-B8B9585A9A7FQ41701208-1B54757C-4B9A-4C72-BEF0-EF0C0206EA00Q47109695-BEB49B2A-08A6-4B9A-BC9F-CEB7E47603A4Q47392563-C20F45BD-6885-4185-9C65-C2C15361EBBDQ47988029-666F9FE4-AE62-4DF6-8766-BF88068BBF04Q48102534-4A60396C-E9B7-4C5E-A3C0-345735481D78Q48850918-E3DAA730-9902-4F72-935B-D60688EDF30CQ49564212-9370C4A2-D2D4-4D14-BBB8-37C408E2CBD9Q49933578-04B54EFC-8391-4757-8A30-91D62BAC8173Q53079838-5DB29027-AABC-4F83-9148-E815FF2E4EADQ55026990-11CAB13D-4594-453D-9196-050293443333Q55167238-4A4F93D9-A7F1-40F2-A5FE-46B1CF8EBA55Q55174959-ECFAFA31-8942-41EA-AED3-7CAF49ADA7EDQ55238969-F81F3A93-5C31-444D-821D-6219DB66B546Q55450758-2ED1CB9A-61BE-455F-B5FF-2AECB8BB8504Q55466488-63F1B52D-4082-4C5A-A693-0BAAD63473F9Q57107866-9B699CDD-5629-4032-B64B-80C6ED272E89Q57495764-D7EAAE91-9770-47B9-B11B-CBAC835F194BQ58768185-467E81B9-325F-4654-B35B-99F7A4790597
P2860
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@ast
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@en
type
label
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@ast
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@en
prefLabel
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@ast
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@en
P2093
P2860
P1433
P1476
Association of Stromal Tumor-I ...... ge HER2-Positive Breast Cancer
@en
P2093
E Aubrey Thompson
Edith A Perez
Frederick L Baehner
Helen Bailey
Karla V Ballman
Kathy S Tenner
Sunil S Badve
P2860
P356
10.1001/JAMAONCOL.2015.3239
P577
2015-10-15T00:00:00Z